Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sabine de Ducla"'
Autor:
Daniel P. Petrylak, Robert Dreicer, Sabine de Ducla, Michiel S. van der Heijden, Jens Bedke, Jonathan E. Rosenberg, Thomas Powles, Yohann Loriot, Jose Luis Perez-Gracia, Simon Fear, Ernest Choy, Lars Thiebach, Axel S. Merseburger, Ignacio Duran, Cora N. Sternberg, Julie Pavlova, Daniel Castellano, Jean H. Hoffman-Censits
Publikováno v:
European urology focus, 7(5), 1084-1091. Elsevier BV
Background The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilis
Autor:
Michiel S. van der Heijden, Robert Huddart, Margitta Retz, Julie Pavlova, Sabine de Ducla, Cora N. Sternberg, Thomas Powles, Simon Fear, Jens Voortman, Michael Ong, Howard Gurney, Craig Gedye, Axel S. Merseburger, Daniel Castellano, Yohann Loriot
Publikováno v:
Merseburger, A S, Castellano, D, Powles, T, Loriot, Y, Retz, M, Voortman, J, Huddart, R A, Gedye, C, Van Der Heijden, M S, Gurney, H, Ong, M, de Ducla, S, Pavlova, J, Fear, S & Sternberg, C N 2021, ' Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma : Subgroup Analyses of the SAUL Study in Real-World Practice ', The Journal of Urology, vol. 206, no. 2, pp. 240-251 . https://doi.org/10.1097/JU.0000000000001768
The Journal of Urology, 206(2), 240-251. Elsevier Inc.
The Journal of Urology, 206(2), 240-251. Elsevier Inc.
PURPOSE: Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety and efficacy in underrepresented sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33498fc9da17966238e1e61b65d590d0
https://research.vumc.nl/en/publications/8ecb94d2-761a-4289-84db-952c5b7aa987
https://research.vumc.nl/en/publications/8ecb94d2-761a-4289-84db-952c5b7aa987
Autor:
Franco Nolè, Iwona Skoneczna, Francesco Massari, Sabine de Ducla, Sjoukje F. Oosting, Robert Huddart, Herlinde Dumez, Ernest Choy, Pablo Maroto, Birute Brasiuniene, Daniel Castellano, Cora N. Sternberg, Yohann Loriot, Teresa Alonso Gordoa, Flavia Di Nucci, Andre P. Fay, Karina Vianna, Simon Fear
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
Aim: Patients with pre-existing autoimmune disease (AID) are typically excluded from clinical trials of immune checkpoint inhibitors, and there are limited data on outcomes in this population. The single-arm international SAUL study of atezolizumab e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca329aacc3d0499c2cc1da1bda62b62
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
Autor:
Andre P. Fay, Begoña Mellado, Craig Gedye, Michael Ong, Simon Fear, Sabine de Ducla, Michaela Matouskova, Laura Milesi, Aristotelis Bamias, Giuseppe Fornarini, Florian Seseke, Michal Mego, Howard Gurney, Jason F. Lester, Daniel Castellano, Robert Huddart, Cora N. Sternberg, Filipa Carneiro, Shahrokh F. Shariat, Jens Voortman
Publikováno v:
Voortman, J 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', ASCO 2020 Virtual Annual Meeting, 01/06/2020 . https://doi.org/10.1200/JCO.2020.38.15_suppl.5035
Castellano, D, Gedye, C, Fornarini, G, Fay, A P, Voortman, J, Mego, M, Bamias, A, Lester, J F, Huddart, R A, Matouskova, M, Gurney, H, Mellado, B, Ong, M, Carneiro, F, Seseke, F, Milesi, L, Shariat, S F, Fear, S, de Ducla, S & Sternberg, C N 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', Journal of Clinical Oncology, vol. 38, no. 15 .
Journal of Clinical Oncology, 38(15). American Society of Clinical Oncology
ASCO 2020 Virtual Annual Meeting
Castellano, D, Gedye, C, Fornarini, G, Fay, A P, Voortman, J, Mego, M, Bamias, A, Lester, J F, Huddart, R A, Matouskova, M, Gurney, H, Mellado, B, Ong, M, Carneiro, F, Seseke, F, Milesi, L, Shariat, S F, Fear, S, de Ducla, S & Sternberg, C N 2020, ' Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study. ', Journal of Clinical Oncology, vol. 38, no. 15 .
Journal of Clinical Oncology, 38(15). American Society of Clinical Oncology
ASCO 2020 Virtual Annual Meeting
5035 Background: Pts with PS > 1 have a poor prognosis and are often excluded from clinical trials. The single-arm SAUL study (NCT02928406) evaluated atezo in a ‘real-world’ population. Overall, safety and efficacy were consistent with prior tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef5cbd4bf0d0e7f1c8c1789adacc962
https://research.vumc.nl/en/publications/d5a561d2-da51-4065-ba25-0af28a6d2458
https://research.vumc.nl/en/publications/d5a561d2-da51-4065-ba25-0af28a6d2458
Autor:
Marija Gamulin, Simon Fear, Thomas Powles, Lajos Géczi, Cora N. Sternberg, Fernando Lopez-Rios, Yohann Loriot, Craig Gedye, Xavier Garcia del Muro, Giuseppe Luigi Banna, Ugo De Giorgi, Friedemann Zengerling, Ignacio Duran, Nicholas D. James, Aristotelis Bamias, Sabine de Ducla, Daniel Castellano, Cristina Masini, Axel S. Merseburger, Ernest Choy
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85ce0d18632cfec253bc60afd1ec8c9
https://hdl.handle.net/10668/13756
https://hdl.handle.net/10668/13756
Autor:
Margitta Retz, Cristina Ligia Cebotaru, Sabine de Ducla, Umberto Basso, Zsuzsanna Kahán, Raymond S. McDermott, Anna Planas Lladó, Javier Puente, Giuseppe Luigi Banna, Florian Seseke, Cora N. Sternberg, Urbano Anido Herranz, Simon Fear, Ugo De Giorgi, Julie Pavlova, Wen Pin Su, Thomas Powles, Álvaro Montesa, Jacques De Greve
Publikováno v:
Journal of Clinical Oncology. 38:5036-5036
5036 Background: Atezo, which targets PD-L1, is an approved therapy for LA/M urothelial carcinoma based on the IMvigor210 and IMvigor211 trials. The single-arm SAUL study (NCT02928406) showed consistent activity and safety in a broader population, in
Autor:
Michiel S. van der Heijden, Jean H. Hoffman-Censits, Yohann Loriot, Viraj Degaonkar, Ernest Choy, Daniel P. Petrylak, Thomas Powles, Daniel Castellano, Sabine de Ducla, Axel S. Merseburger, Jose Luis Perez-Gracia, Ignacio Duran, Lars Thiebach, Jonathan E. Rosenberg, Cora N. Sternberg, Jens Bedke, Simon Fear, Robert Dreicer
Publikováno v:
Journal of Clinical Oncology. 38:492-492
492 Background: Atezo is an approved therapy for mUC based on the IMvigor210 (IM210) and IMvigor211 (IM211) phase 2 and 3 trials. The single-arm phase 3b SAUL study in a broader patient (pt) population showed consistent efficacy and safety. The value
Autor:
Yohann Loriot, Laurence Eliot Miles Krieger, Guy Faust, Michiel S. van der Heijden, Simon Fear, María José Méndez Vidal, Andrea Necchi, Zsuzsanna Papai, Olatz Etxaniz, Sabine de Ducla, Axel S. Merseburger, Consuelo Buttigliero, Nuria Lainez, Rosa Tambaro, Andres Felipe Cardona Zorrilla, Franco Morelli, Margitta Retz, Cora N. Sternberg, Maartje Los, Stefano Panni
Publikováno v:
Journal of Clinical Oncology. 38:488-488
488 Background: UTUC is rarer than bladder UC and typically responds poorly to standard chemotherapy. Analysis of 220 biomarker-evaluable atezo-treated patients (pts) in phase II/III trials suggested worse outcomes in UT vs lower tract UC [Galsky, ES
Autor:
Dinesh Chandra Doval, Giorgio Mustacchi, Sabine de Ducla, Guillermo Lopez Vivanco, Xiaojia Wang, Paulo Cortes, Lesley Fallowfield, Hakan Bozcuk, Ewa Chmielowska, Ulrich Freudensprung, Joseph Gligorov, Alfred Elias Namour, Sudeep Gupta, Saverio Cinieri, Jean-Yves Pierga, José Bines, Philippe Montcuquet, Vineet Gupta, Kadri Altundag, Emilio Alba
Publikováno v:
Cancer Research. 75:P2-12
BACKGROUND The addition of CAP to maintenance BEV demonstrated statistically significant and clinically relevant improvements in progression-free survival (PFS [primary endpoint]; HR 0.38 [95% CI 0.27–0.55]; log-rank p METHODS Pts with HER2-negativ
Autor:
Mikkel Z. Oestergaard, Gunter von Minckwitz, István Láng, Andrea Fontana, Cristian Villanueva, Sabine de Ducla, Eduard Vrdoljak, Joseph Gligorov, Gilles Romieu, Norbert Marschner, Eva Ciruelos, Javier Cortes, Ulrich Freudensprung, Christoph C. Zielinski, Corinne Veyret, Fabio Puglisi
Publikováno v:
Cancer Research. 75:P3-06
BACKGROUND: A potential predictive and prognostic effect of pretreatment pVEGF-A concentrations was suggested in exploratory analyses of phase III trials in HER2-negative mBC (AVADO), gastric cancer (AVAGAST), and pancreatic cancer (AViTA). This led